Related Articles
Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)
Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)